The enhanced genomic 6 mA metabolism contributes to the proliferation and migration of TSCC cells

Abstract

In contrast to the well-established genomic 5-methylcytosine (5mC), the existence of N⁶-methyladenine (6 mA) in eukaryotic genomes was discovered only recently. Initial studies found that it was actively regulated in cancer cells, suggesting its involvement in the process of carcinogenesis. However, the contribution of 6 mA in tongue squamous cell carcinoma (TSCC) still remains uncharacterized. In this study, a pan-cancer type analysis was first performed, which revealed enhanced 6 mA metabolism in diverse cancer types. The study was then focused on the regulation of 6 mA metabolism, as well as its effects on TSCC cells. To these aspects, genome 6 mA level was found greatly increased in TSCC tissues and cultured cells. By knocking down 6 mA methylases N6AMT1 and METTL4, the level of genomic 6 mA was decreased in TSCC cells. This led to suppressed colony formation and cell migration. By contrast, knockdown of 6 mA demethylase ALKBH1 resulted in an increased 6 mA level, enhanced colony formation, and cell migration. Further study suggested that regulation of the NF-κB pathway might contribute to the enhanced migration of TSCC cells. Therefore, in the case of TSCC, we have shown that genomic 6 mA modification is involved in the proliferation and migration of cancer cells.

References

[1] Fu Y, . N6-methyldeoxyadenosine marks active transcription start sites in Chlamydomonas. Cell, 2015, 161: 879-892.

[2] Greer EL, . DNA methylation on N6-adenine in C. elegans. Cell, 2015, 161: 868-878.

[3] Zhang G, . N6-methyladenine DNA modification in Drosophila. Cell, 2015, 161: 893-906.

[4] Liu J, . Abundant DNA 6mA methylation during early embryogenesis of zebrafish and pig. Nat. Commun., 2016, 7

[5] Wu TP, . DNA methylation on N(6)-adenine in mammalian embryonic stem cells. Nature, 2016, 532: 329-333.

[6] Mondo SJ, . Widespread adenine N6-methylation of active genes in fungi. Nat. Genet., 2017, 49: 964-968.

[7] Liang Z, . DNA N(6)-adenine methylation in Arabidopsis thaliana. Dev. Cell, 2018, 45: 406-416. e403

[8] Xiao CL, . N(6)-methyladenine DNA modification in the human genome. Mol. Cell, 2018, 71: 306-318. e307

[9] Kweon SM, . An adversarial DNA N(6)-methyladenine-sensor network preserves polycomb silencing. Mol. Cell, 2019, 74: 1138-1147. e1136

[10] Zhang Z, . Regulation of adipocyte differentiation by METTL4, a 6 mA methylase. Sci. Rep., 2020, 10

[11] Liang D, . The decreased N(6)-methyladenine DNA modification in cancer cells. Biochem. Biophys. Res. Commun., 2016, 480: 120-125.

[12] Xie Q, . N(6)-methyladenine DNA modification in glioblastoma. Cell, 2018, 175: 1228-1243. e1220

[13] Chen L, Zhang M, Guo M. DNA N6-methyladenine increased in human esophageal squamous cell carcinoma. Discov. Med., 2020, 29: 85-90.

[14] Cai X, Huang J. Distant metastases in newly diagnosed tongue squamous cell carcinoma. Oral. Dis., 2019, 25: 1822-1828.

[15] Rani P, . Clinicopathological correlation of tumor-stroma ratio and inflammatory cell infiltrate with tumor grade and lymph node metastasis in squamous cell carcinoma of buccal mucosa and tongue in 41 cases with review of literature. J. Cancer Res. Ther., 2020, 16: 445-451.

[16] Barrett AW, . Perineural and lymphovascular invasion in squamous cell carcinoma of the tongue. Oral Pathol. Med., 2021, 50: 32-38.

[17] Ng JH, Iyer NG, Tan M-H, Edgren G. Changing epidemiology of oral squamous cell carcinoma of the tongue: a global study. Head Neck, 2017, 39: 297-304.

[18] Satgunaseelan L, . The incidence of squamous cell carcinoma of the oral tongue is rising in young non-smoking women: an international multi-institutional analysis. Oral. Oncol., 2020, 110: 104875.

[19] Best DL, Spresser W, Shivers P, Edwards SP, Ward BB. Squamous cell carcinoma of the tongue in young patients: a case series and literature review. J. Oral Maxillofac. Surg., 2021, 79: 1270-1286.

[20] Yu M, . Identification of a potential target for treatment of squamous cell carcinoma of the tongue: follistatin. Br. J. Oral Maxillofac. Surg., 2020, 58: 437-442.

[21] Colella G, . Clinical management of squamous cell carcinoma of the tongue: patients not eligible for free flaps, a systematic review of the literature. Expert Rev. Anticancer Ther., 2021, 21: 9-22.

[22] Zhang S, . Genome-wide analysis of DNA methylation in tongue squamous cell carcinoma. Oncol. Rep., 2013, 29: 1819-1826.

[23] Chen H-C, . Global DNA hypomethylation is associated with the development and poor prognosis of tongue squamous cell carcinoma. J. Oral Pathol. Med., 2016, 45: 409-417.

[24] Bhat S, . Gene promoter-associated CpG island hypermethylation in squamous cell carcinoma of the tongue. Virchows Arch., 2017, 470: 445-454.

[25] Hall BG. Building phylogenetic trees from molecular data with MEGA. Mol. Biol. Evol., 2013, 30: 1229-1235.

[26] Chandrashekar DS, . UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia, 2017, 19: 649-658.

[27] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011, 144: 646-674.

[28] Aparna M, Rao L, Kunhikatta V, Radhakrishnan R. The role of MMP-2 and MMP-9 as prognostic markers in the early stages of tongue squamous cell carcinoma. Oral Pathol. Med., 2015, 44: 345-352.

[29] Ciucă FI, . The prognostic value of CXCR4, MMP-2 and MMP-9 in tongue squamous carcinoma. Rom. Rom. J. Morphol. Embryol., 2019, 60: 59-68.

[30] de Matos FR, . Association of polymorphisms in IL-8, MMP-1 and MMP-13 with the risk and prognosis of oral and oropharyngeal squamous cell carcinoma. Arch. Oral. Biol., 2019, 108: 104547.

[31] Yuan J, . LncRNA MALAT1 expression inhibition suppresses tongue squamous cell carcinoma proliferation, migration and invasion by inactivating PI3K/Akt pathway and downregulating MMP-9 expression. Eur. Rev. Med. Pharmacol. Sci., 2019, 23: 198-206.

[32] Nascimento G, . Polymorphisms of matrix metalloproteinase-7 and -9 are associated with oral tongue squamous cell carcinoma. Braz. Oral Res., 2020, 35: e019.

[33] Rai KH, Ahmed J. A correlative study of N-cadherin expression with different grades of oral squamous cell carcinoma projecting as a marker of epithelial to mesenchymal transition in tumor progression. Asian Pac. J. Cancer Prev., 2019, 20: 2327-2332.

[34] Liu PF, . Vimentin is a potential prognostic factor for tongue squamous cell carcinoma among five epithelial-mesenchymal transition-related proteins. PLoS ONE, 2017, 12: e0178581.

[35] Zhao, R. et al. IGFL2-AS1 facilitates tongue squamous cell carcinoma progression via Wnt/β-catenin signaling pathway. Oral Dis. (2021). https://doi.org/10.1111/odi.13935. (Online ahead of print).

[36] Wu, Y. et al. Telomerase reverse transcriptase mediates EMT through NF-κB signaling in tongue squamous cell carcinoma. Oncotarget 8, 85492–85503 (2017).

[37] Chen WC, . Xenotropic and polytropic retrovirus receptor 1 (XPR1) promotes progression of tongue squamous cell carcinoma (TSCC) via activation of NF-κB signaling. J. Exp. Clin. Cancer Res., 2019, 38: 167.

[38] Daskalopoulos AG, . Assessment of TLR4 and TLR9 signaling and correlation with human papillomavirus status and histopathologic parameters in oral tongue squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol., 2020, 129: 493-513.

[39] Serpa MS, . Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue. Braz. Oral. Res., 2018, 32: e93.

[40] Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev., 2007, 26: 717-724.

[41] Decock J, Thirkettle S, Wagstaff L, Edwards DR. Matrix metalloproteinases: protective roles in cancer. J. Cell. Mol. Med, 2011, 15: 1254-1265.

[42] Juurikka, K., Butler, G. S., Salo, T., Nyberg, P. & Åström, P. The role of mmp8 in cancer: a systematic review. Int. J. Mol. Sci. 20, 4506 (2019).

[43] Ma B, Ran R, Liao HY, Zhang HH. The paradoxical role of matrix metalloproteinase-11 in cancer. Biomed. Pharmacother., 2021, 141: 111899.

[44] Bates SE. Epigenetic therapies for cancer. N. Engl. J. Med., 2020, 383: 650-663.

[45] Lee ST, Wiemels JL. Genome-wide CpG island methylation and intergenic demethylation propensities vary among different tumor sites. Nucleic Acids Res., 2016, 44: 1105-1117.

[46] Hao, Z. et al. N(6)-deoxyadenosine methylation in mammalian mitochondrial DNA. Mol. Cell 78, 382–395 (2020).

[47] Liang Z, Kidwell RL, Deng H, Xie Q. Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer. Cancer Biol. Med., 2020, 17: 9-19.

[48] Wu KJ. The epigenetic roles of DNA N(6)-methyladenine (6mA) modification in eukaryotes. Cancer Lett., 2020, 494: 40-46.

[49] Alderman MH 3rd, Xiao AZ. N(6)-methyladenine in eukaryotes. Cell Mol. Life Sci., 2019, 76: 2957-2966.

Funding

Beijing Health Science and Technology Promotion Project (BHTPP202027) Beijing Li Huanying Medical Foundation (lhyjjhzzxm2021-01)